Updated:
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals, led by CEO Peter Greenleaf, commercializes the first FDA-approved oral therapy for lupus nephritis in decades.
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals was formed in 2013 through the merger of Isotechnika Pharma and privately held Aurinia Pharma, inheriting voclosporin, a calcineurin inhibitor originally explored in organ transplant rejection. CEO Peter Greenleaf, previously of Sucampo and Cerecor, joined in 2019 and immediately refocused the company around a single regulatory path: lupus nephritis, an autoimmune kidney condition with no new FDA-approved therapy in decades. That bet paid out in January 2021 when the FDA approved Lupkynis (voclosporin) in combination with standard-of-care immunosuppressants. The company's wealth origin is not tied to a family fortune — it is publicly traded and institutional backed. Aurinia's deployment is narrow by design. Nearly all capital flows into supporting Lupkynis, a second-line therapy for active lupus nephritis, in the US market. The company operates a specialty pharmacy and patient-hub model — Aurinia Alliance — handling distribution, co-pay assistance, and adherence monitoring in-house rather than outsourcing to a large CRO. Globally, it struck a 2020 licensing deal with Otsuka Pharmaceutical for Europe and Japan, leaving Aurinia concentrated on North American commercialization. There is no sprawling pipeline; a Phase 2/3 trial for pediatric lupus nephritis (per ClinicalTrials.gov) and an earlier-stage effort in dry eye syndrome represent the only visible R&D bets beyond label expansion. The company publicly carries no meaningful AUM metric — it is an operating entity, not an allocator. As of its most recent filings, Aurinia reported roughly $350 million in cash and equivalents and a market capitalization fluctuating around $1.2 billion. Its operational cash burn is offset by growing Lupkynis revenue, which crossed $100 million annually in 2023 (per the firm, 2023). Headcount remains lean relative to commercial peers, with teams split between Victoria, British Columbia and Rockville, Maryland. March 2024: The company disclosed that its CFO, Joe Miller, would depart, prompting an external search for a replacement — a governance transition closely watched by investors given the single-product concentration risk. Aurinia's structural differentiator is its status as a commercial-stage orphan-drug company with no research engine. Unlike peers that plow revenue into discovery platforms or M&A, Aurinia functions as a pure-play asset vehicle for voclosporin. Its next-decade value rests entirely on whether Greenleaf can extend the Lupkynis franchise into pediatric use and defend against inevitable generic erosion — a binary outcome shaped far more by regulatory and pricing decisions than by scientific risk.
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Victoria
Corporate office
Victoria, British Columbia, Canada
Additional offices
Rockville, Maryland, United States
Principals
Peter Greenleaf
President and Chief Executive Officer
Sector focus
Frequently asked questions
What is Aurinia Pharmaceuticals' lead asset and how is it positioned?
Aurinia's sole commercial product is Lupkynis (voclosporin), a calcineurin inhibitor approved by the FDA in January 2021 for adult patients with active lupus nephritis. It is administered alongside mycophenolate mofetil and corticosteroids — the prior standard of care. The drug competes directly with GSK's Benlysta but holds the advantage of being oral rather than intravenous or subcutaneous (per the company's label).
How does Aurinia structure its commercial operations?
The company operates a proprietary patient-services hub called Aurinia Alliance, which handles specialty pharmacy distribution, insurance navigation, and co-pay assistance for Lupkynis patients in the United States. This in-house model allows the firm to capture margin and patient-adherence data that would otherwise flow to a third-party hub provider. The arrangement is atypical for a biotech of Aurinia's size.
Does Aurinia have any clinical-stage programs beyond lupus nephritis?
Yes, the pipeline is thin but not empty. A Phase 2/3 trial is evaluating voclosporin in adolescent patients with lupus nephritis, and a separate early-stage trial is investigating an ophthalmic formulation of voclosporin (VOS) for dry eye syndrome. Both are listed on ClinicalTrials.gov as active but represent small bets relative to the commercial franchise.
What is Aurinia's geographic footprint and partnership strategy?
Aurinia retains full commercial rights in the United States and Canada, while Otsuka Pharmaceutical licensed rights for the European Union, Japan, and several other territories in a 2020 deal worth up to $50 million upfront plus milestones (per the firm's regulatory filings). Aurinia's micro-footprint — two offices in British Columbia and Maryland — reflects its lean operational philosophy.
Who controls investment and strategic decisions at Aurinia?
As a publicly traded company, Aurinia's board and executive team set strategy. CEO Peter Greenleaf holds the dominant operational voice. The company also contended in 2023 with an activist campaign from MKT Capital, which pushed for strategic alternatives including a potential sale, signaling that external allocators view the single-asset structure as a risk-arbitrage opportunity rather than a long-duration hold (per public proxy materials).
Is Aurinia structured as a family office or an operating company?
Aurinia Pharmaceuticals is a commercial-stage biotech and a fully public corporation — not a family office. It appears in an Altss entity profile because it represents a large, institutionally held healthcare position that family offices may evaluate as a public-equity holding or as context for private biotech allocations.
What is Aurinia's primary risk that institutional investors cite?
Single-asset concentration risk. The company's entire revenue derives from Lupkynis in the US lupus nephritis market, which is small by pharma blockbuster standards. A generic challenge prior to the patent cliff — voclosporin's key US patent expires in 2039 — or a payer-driven formulary win for Benlysta would dramatically reduce forward revenue, leaving the pediatric and dry-eye programs as insufficient offsets.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: